No Data
No Data
Shuttle Pharmaceuticals Enters Revolving Loan Agreement
Express News | Shuttle Pharmaceuticals Holdings Inc - Enters $2 Million Revolving Loan Agreement
Shuttle Pharmaceuticals Provides Corporate Update On Phase 2 Glioblastoma Trial Enrollment, Diagnostics Advancements With UCSF, Launch Of New Corporate Website, And $237,500 Investment By CEO Dr. Anatoly Dritschilo And Other Investors In Recent Financing
Express News | Shuttle Pharmaceuticals FY24 EPS $(3.30) Vs $(3.53) YoY
Shuttle Pharma Provides Corporate Update and Reports 2024 Results
Shuttle Pharmaceuticals | 10-K: FY2024 Annual Report